{"uri": "eng-9421849", "concepts": [{"uri": "http://en.wikipedia.org/wiki/Ovarian_cancer", "type": "wiki", "score": 100, "label": {"eng": "Ovarian cancer"}}, {"uri": "http://en.wikipedia.org/wiki/Food_and_Drug_Administration", "type": "wiki", "score": 98, "label": {"eng": "Food and Drug Administration"}}, {"uri": "http://en.wikipedia.org/wiki/Cancer", "type": "wiki", "score": 89, "label": {"eng": "Cancer"}}, {"uri": "http://en.wikipedia.org/wiki/Fallopian_tube", "type": "wiki", "score": 64, "label": {"eng": "Fallopian tube"}}, {"uri": "http://en.wikipedia.org/wiki/Epithelium", "type": "wiki", "score": 64, "label": {"eng": "Epithelium"}}, {"uri": "http://en.wikipedia.org/wiki/AbbVie_Inc.", "type": "org", "score": 63, "label": {"eng": "AbbVie Inc."}}, {"uri": "http://en.wikipedia.org/wiki/Peritoneum", "type": "wiki", "score": 59, "label": {"eng": "Peritoneum"}}, {"uri": "http://en.wikipedia.org/wiki/Survival_rate", "type": "wiki", "score": 52, "label": {"eng": "Survival rate"}}, {"uri": "http://en.wikipedia.org/wiki/Chemotherapy", "type": "wiki", "score": 50, "label": {"eng": "Chemotherapy"}}, {"uri": "http://en.wikipedia.org/wiki/Surgery", "type": "wiki", "score": 48, "label": {"eng": "Surgery"}}, {"uri": "http://en.wikipedia.org/wiki/Antibody-drug_conjugate", "type": "wiki", "score": 44, "label": {"eng": "Antibody-drug conjugate"}}, {"uri": "http://en.wikipedia.org/wiki/Folate_receptor", "type": "wiki", "score": 43, "label": {"eng": "Folate receptor"}}, {"uri": "http://en.wikipedia.org/wiki/Neoplasm", "type": "wiki", "score": 41, "label": {"eng": "Neoplasm"}}, {"uri": "http://en.wikipedia.org/wiki/Platinum-based_antineoplastic", "type": "wiki", "score": 35, "label": {"eng": "Platinum-based antineoplastic"}}, {"uri": "http://en.wikipedia.org/wiki/Progression-free_survival", "type": "wiki", "score": 35, "label": {"eng": "Progression-free survival"}}, {"uri": "http://en.wikipedia.org/wiki/Clinical_endpoint", "type": "wiki", "score": 35, "label": {"eng": "Clinical endpoint"}}, {"uri": "http://en.wikipedia.org/wiki/Statistical_significance", "type": "wiki", "score": 35, "label": {"eng": "Statistical significance"}}, {"uri": "http://en.wikipedia.org/wiki/Peripheral_neuropathy", "type": "wiki", "score": 31, "label": {"eng": "Peripheral neuropathy"}}, {"uri": "http://en.wikipedia.org/wiki/Eye", "type": "wiki", "score": 31, "label": {"eng": "Eye"}}, {"uri": "http://en.wikipedia.org/wiki/Topotecan", "type": "wiki", "score": 30, "label": {"eng": "Topotecan"}}, {"uri": "http://en.wikipedia.org/wiki/Paclitaxel", "type": "wiki", "score": 30, "label": {"eng": "Paclitaxel"}}, {"uri": "http://en.wikipedia.org/wiki/ImmunoGen", "type": "org", "score": 27, "label": {"eng": "ImmunoGen"}}], "eventDate": "2024-03-22", "totalArticleCount": 9, "title": {"eng": "FDA grants full approval to AbbVie's ovarian cancer drug By Investing.com"}, "summary": {"eng": "NORTH CHICAGO, Ill. - AbbVie (NYSE: NYSE:ABBV) has received full approval from the U.S. Food and Drug Administration (FDA) for ELAHERE\u00ae (mirvetuximab soravtansine-gynx) as a treatment for a specific type of ovarian cancer. This marks a significant milestone for the pharmaceutical company, particularly after its recent acquisition of ImmunoGen (NASDAQ:IMGN), which developed the drug.\n\nELAHERE is now approved for adult patients with folate receptor alpha (FR\u03b1)-positive, platinum-resistant epithel"}, "location": null, "categories": [{"uri": "dmoz/Health/Conditions_and_Diseases/Cancer", "label": "dmoz/Health/Conditions and Diseases/Cancer", "wgt": 78}, {"uri": "dmoz/Health/Men's_Health/Conditions_and_Diseases", "label": "dmoz/Health/Men's Health/Conditions and Diseases", "wgt": 100}, {"uri": "news/Health", "label": "news/Health", "wgt": 67}], "articleCounts": {"eng": 9}, "sentiment": -0.02745098039215688, "wgt": 448761600, "relevance": 1}